Cardiovascular Risk in Ulcerative Colitis
Patients with ulcerative colitis face an elevated cardiovascular risk that is most pronounced during active disease and in younger patients, requiring aggressive control of intestinal inflammation alongside traditional cardiovascular risk factor management.
Understanding the Cardiovascular Risk
Ulcerative colitis patients have an increased risk of atherosclerotic cardiovascular disease (ASCVD), venous thromboembolism (VTE), and other cardiovascular events that cannot be fully explained by traditional risk factors alone 1. The excess risk is driven by:
- Chronic systemic inflammation promoting endothelial dysfunction, hypercoagulability, and accelerated atherogenesis
- Active mucosal inflammation - patients without mucosal healing show significantly increased odds of asymptomatic carotid or femoral vascular disease (48.15% vs 26.67% in controls) 2
- The "lipid paradox" - reduced circulating lipid levels paradoxically coexist with increased cardiovascular risk due to inflammation-mediated lipoprotein dysfunction 1
- Intestinal barrier disruption with microbial translocation and dysbiosis
- Dysfunctional visceral adipose tissue contributing to metabolic dysfunction
Risk Magnitude in Real-World Practice
Recent data from UC patients initiating advanced therapies showed that most have 0-1 VTE risk factors (61%), with elevated CRP being most common (45%) 3. During median follow-up of 27 months, the actual incidence of VTE and CV events was low (0.59 per 100 person-years), suggesting baseline risk is manageable with appropriate therapy 3.
Risk Assessment Strategy
Identify High-Risk Patients
Highest risk patients include:
- Those with active endoscopic disease (not just symptomatic disease)
- Younger patients during disease flares
- Patients requiring hospitalization for severe UC
- Those with elevated inflammatory markers (CRP, ESR)
- Elderly patients with traditional CV risk factors
Cardiovascular Risk Evaluation
- Use traditional risk calculators (ASCVD, SCORE2) but recognize they likely underestimate risk in IBD patients 1, 4
- Assess for subclinical atherosclerosis with carotid/femoral ultrasound to detect abnormal intima-media thickness, particularly in patients with persistently active disease 2
- Screen for VTE risk factors including prior thrombotic events, family history, immobility, and active inflammation
Critical Pitfall to Avoid
Do not rely solely on symptom control - endoscopic disease activity matters. Patients in clinical remission but without mucosal healing remain at elevated cardiovascular risk 2.
Management Approach
Primary Strategy: Control Intestinal Inflammation
The most important intervention is achieving and maintaining mucosal healing 1, 4. This directly addresses the inflammatory driver of cardiovascular risk.
- Use advanced therapies (biologics, JAK inhibitors, S1P modulators) as indicated per AGA guidelines 5
- Prioritize mucosal healing as a treatment target, not just symptom control
- Minimize corticosteroid exposure, which increases cardiovascular risk 1
Thromboprophylaxis
During severe UC requiring hospitalization:
- Administer subcutaneous low-molecular-weight heparin for VTE prophylaxis (Grade B recommendation) 6, 7, 6
- This is essential as thromboembolism risk is markedly elevated during flares and is independent of other risk factors 7
Medication-Specific Cardiovascular Considerations
JAK Inhibitors (Tofacitinib, Upadacitinib, Filgotinib):
- Higher doses of tofacitinib show increased risk of pulmonary embolism and all-cause mortality 5
- JAK inhibitors may increase risk of major adverse cardiovascular events (MACE) and cancer in older adults (>50 years) with cardiovascular risk factors (smoking, prior CV disease) 8, 9
- Avoid in patients with established cardiovascular disease or multiple risk factors unless benefits clearly outweigh risks
- Use maintenance dose of tofacitinib 5mg twice daily rather than higher doses when possible 5
Anti-TNF Agents:
- Infliximab associated with increased reporting of heart failure and arrhythmias, particularly in patients with pre-existing cardiac disease 9
- Use with caution in patients with known heart failure
Vedolizumab and Ustekinumab:
- Show consistently favorable cardiovascular safety profiles across trials and real-world studies 8, 9
- Preferred in patients with cardiovascular risk factors or established disease
IL-23 Inhibitors (Risankizumab, Mirikizumab, Guselkumab):
- Generally low CV event rates, though signals for atrial fibrillation have emerged with risankizumab 9
S1P Receptor Modulators (Ozanimod, Etrasimod):
- Carry class-specific cardiovascular warnings
- Require careful cardiac monitoring at initiation
Traditional Cardiovascular Risk Factor Management
Aggressively treat modifiable risk factors:
- Smoking cessation (mandatory)
- Hypertension control
- Diabetes management
- Dyslipidemia treatment
- Weight management and physical activity
Important note: Traditional cardiovascular medications (statins, antihypertensives, antiplatelet agents) do not adversely affect IBD course and should be used as indicated 4.
Practical Algorithm
For all UC patients:
- Assess endoscopic disease activity - target mucosal healing
- Minimize corticosteroid exposure
- Screen for traditional CV risk factors
For patients with active disease:
- Intensify anti-inflammatory therapy to achieve mucosal healing
- If hospitalized with severe UC: initiate LMWH prophylaxis
- Consider carotid/femoral ultrasound if persistently active disease
When selecting advanced therapy:
- If age >50 with CV risk factors or established CV disease: Prefer vedolizumab, ustekinumab, or IL-23 inhibitors over JAK inhibitors
- If known heart failure: Avoid infliximab; prefer vedolizumab or ustekinumab
- If low CV risk and biologic-naïve: Follow standard efficacy-based selection per AGA guidelines 8, 10
- If requiring JAK inhibitor with CV risk factors: Use lowest effective dose, monitor closely for MACE
Ongoing monitoring:
- Reassess CV risk annually
- Monitor inflammatory markers and endoscopic activity
- Adjust therapy to maintain mucosal healing